Top

Published in:

01-03-2011 | Focussed Research Review

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

Authors: Rupal Ramakrishnan, Dmitry I. Gabrilovich

Published in: Cancer Immunology, Immunotherapy | Issue 3/2011

Abstract

In recent years, the combination of cancer immunotherapy with standard therapeutic modality is gaining credibility due to a number of clinical trials demonstrating therapeutic success of such combination therapies. However, the mechanism of this phenomenon is poorly understood. Here, we will discuss recent findings that suggest novel mechanisms of synergistic effect of cancer immunotherapy and chemotherapy.

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915CrossRefPubMed

Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD et al (2005) Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11(12):4430–4436CrossRefPubMed

Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH et al (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12(3 Pt 1):878–887CrossRefPubMed

Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4):1260–1269CrossRefPubMed

Schlom J, Arlen PM, Gulley JL (2007) Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13(13):3776–3782CrossRefPubMed

Wheeler CJ, Das A, Liu G, Yu JS, Black KL (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10(16):5316–5326CrossRefPubMed

Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA et al (2006) Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20(1):29–34CrossRefPubMed

Liseth K, Ersvaer E, Hervig T, Bruserud O (2010) Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010:692097PubMed

Shurin GV, Tourkova IL, Kaneno R, Shurin MR (2009) Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183(1):137–144CrossRefPubMed

10.

Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A (2009) Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 69(17):6987–6994CrossRefPubMed

11.

Green DR, Ferguson T, Zitvogel L, Kroemer G (2009) Immunogenic and tolerogenic cell death. Nat Rev Immunol 9(5):353–363CrossRefPubMed

12.

Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV (2007) Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109(11):4839–4845CrossRefPubMed

13.

Jensen H, Andresen L, Hansen KA, Skov S (2009) Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity. J Leukoc Biol 86(4):923–932CrossRefPubMed

14.

Bergmann-Leitner ES, Abrams SI (2001) Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 50(9):445–455CrossRefPubMed

15.

Herber DL, Nagaraj S, Djeu JY, Gabrilovich DI (2007) Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 67(11):5067–5069CrossRefPubMed

16.

Emens LA, Jaffee EM (2005) Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65(18):8059–8064CrossRefPubMed

17.

Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC et al (2001) Novel allogeneic granulocyte-macrophage colony-stimulating factor–secreting tumor vaccine for pancreatic cancer: a phase i trial of safety and immune activation. J Clin Oncol 19:145–156PubMed

18.

Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120(4):1111–1124CrossRefPubMed

19.

Chada S, Mhashilkar A, Roth JA, Gabrilovich D (2003) Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel 6(2):169–173PubMed

20.

Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ 3rd, Liu ET, Conway K (2000) HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 18(2):267–274PubMed

21.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23(9):974–979CrossRefPubMed

22.

Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(Suppl 6):S3–S6PubMed

23.

Sartiano GP, Lynch WE, Bullington WD (1979) Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha. J Antibiot (Tokyo) 32(10):1038–1045

24.

Reedijk J, Lohman PH (1985) Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci 7(5):173–180PubMed

25.

Lowin B, Hahne M, Mattmann C, Tschopp J (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370(6491):650–652CrossRefPubMed

26.

Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76(6):977–987CrossRefPubMed

27.

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360CrossRefPubMed

28.

Xu X, Fu XY, Plate J, Chong AS (1998) IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 58(13):2832–2837PubMed

29.

Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR, Kiefer MC (1997) Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 272(26):16351–16357CrossRefPubMed

30.

Henkart PA, Sitkovsky MV (1994) Cytotoxic lymphocytes. Two ways to kill target cells. Curr Biol 4(10):923–925CrossRefPubMed

31.

Raja SM, Wang B, Dantuluri M, Desai UR, Demeler B, Spiegel K, Metkar SS, Froelich CJ (2002) Cytotoxic cell granule-mediated apoptosis. Characterization of the macromolecular complex of granzyme B with serglycin. J Biol Chem 277(51):49523–49530CrossRefPubMed

32.

Trapani JA, Davis J, Sutton VR, Smyth MJ (2000) Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol 12(3):323–329CrossRefPubMed

33.

Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleackley RC (2000) Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 192(10):1391–1402CrossRefPubMed

34.

Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, Browne KA, Trapani JA (2000) Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 192(10):1403–1414CrossRefPubMed

35.

Thomas DA, Scorrano L, Putcha GV, Korsmeyer SJ, Ley TJ (2001) Granzyme B can cause mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK. Proc Natl Acad Sci USA 98(26):14985–14990CrossRefPubMed

36.

Shi L, Mai S, Israels S, Browne K, Trapani JA, Greenberg AH (1997) Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med 185(5):855–866CrossRefPubMed

37.

Pinkoski MJ, Hobman M, Heibein JA, Tomaselli K, Li F, Seth P, Froelich CJ, Bleackley RC (1998) Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. Blood 92(3):1044–1054PubMed

38.

Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, Dixit VM, Hanna W (1996) New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 271(46):29073–29079CrossRefPubMed

39.

Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF et al (2000) Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103(3):491–500CrossRefPubMed

40.

Stein M, Braulke T, Krentler C, Hasilik A, von Figura K (1987) 46-kDa mannose 6-phosphate-specific receptor: biosynthesis, processing, subcellular location and topology. Biol Chem Hoppe Seyler 368(8):937–947PubMed

41.

Stein M, Zijderhand-Bleekemolen JE, Geuze H, Hasilik A, von Figura K (1987) Mr 46, 000 mannose 6-phosphate specific receptor: its role in targeting of lysosomal enzymes. EMBO J 6(9):2677–2681PubMed

42.

Griffiths G, Hoflack B, Simons K, Mellman I, Kornfeld S (1988) The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52(3):329–341CrossRefPubMed

43.

O’Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD (2002) Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143(11):4287–4294CrossRefPubMed

44.

Zaina S, Squire S (1998) The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. J Biol Chem 273(44):28610–28616CrossRefPubMed

45.

Li J, Sahagian GG (2004) Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 23(58):9359–9368CrossRefPubMed

46.

Dressel R, Raja SM, Honing S, Seidler T, Froelich CJ, von Figura K, Gunther E (2004) Granzyme-mediated cytotoxicity does not involve the mannose 6-phosphate receptors on target cells. J Biol Chem 279(19):20200–20210CrossRefPubMed

47.

Trapani JA, Sutton VR, Thia KY, Li YQ, Froelich CJ, Jans DA, Sandrin MS, Browne KA (2003) A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J Cell Biol 160(2):223–233CrossRefPubMed

Title: Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer
Authors: Rupal Ramakrishnan
Dmitry I. Gabrilovich
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-010-0930-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination

Acknowledgement

Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients

Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications

Keynote webinar | Spotlight on antibody–drug conjugates in cancer